

## Poly(glycerol sebacate) nanoparticles for encapsulation of hydrophobic anti-cancer drugs

Benoit Louage,<sup>a</sup> Liesa Tack,<sup>a</sup> Yadong Wang,<sup>b\*</sup> Bruno G. De Geest<sup>a\*</sup>

<sup>a</sup> Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

<sup>b</sup> Departments of Bioengineering, Chemical and Petroleum Engineering, Surgery, Mechanical Engineering and Materials Science, and the McGowan Institute for Regenerative Medicine, 3700 O'Hara Street, 411 Benedum Hall, Pittsburgh, PA 15261, USA







Figure S1. Size exclusion chromatography (SEC)-elugram of PGS.




**Figure S2.** Digital photographs PGS nanoparticles (B), PTX/PGS nanoparticles (C) and pure PTX formulated in H<sub>2</sub>O (D), compared with pure H<sub>2</sub>O (A).



**Figure S3.** Digital photographs PGS nanoparticles (B), PTX/PGS nanoparticles (C) and pure PTX formulated in physiological glucose solution (i.e. dextrose 5 %) (D), compared with pure dextrose 5 % (A).



**Figure S4.** Size (A) and 48-hour stability (B) of PGS and PGS/PTX nanoparticles in dextrose 5 %, measured by DLS at 25 °C.



**Figure S5.** Size distribution (intensity) of PGS/FLU nanoparticles measured by DLS.